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Summary 
The proficiency test for antibiotics in bovine muscle was organized by Rikilt - Institute of Food Safety 
and in accordance with ISO/IEC Guide 43-1 and 43-2 and ILAC-G13. The quantitative and 
confirmatory part was carried out under accreditation (Dutch Accreditation Board, ILAC-G13). 
 
For this proficiency study, three test materials were prepared: 
 a blank bovine muscle material; 
 a bovine muscle material containing oxytetracycline aimed at 120 µg/kg; 
 a bovine muscle material containing sulfachlorpyridazine aimed at 90 µg/kg, sulfadimidine aimed at 
120 µg/kg and dapson aimed at 5 µg/kg. 
 
The materials containing antibiotics were all prepared by spiking blank bovine muscle materials 
followed by cryogenic homogenization. During homogeneity testing, all materials proved to be 
sufficiently homogenous for proficiency testing. The stability test demonstrated that no statistically 
significant loss of oxytetracycline and sulfadimidine occurred during the timescale of the proficiency 
test. For sulfachloropyridazine and dapson a minor loss occurred during the thaw-freeze cycle that was 
included in the stability test. 
 
The participating laboratories were first asked to carry out a screening analysis. After reporting the 
screening results they were asked to carry out a quantitative confirmatory analysis for the compounds 
found suspect and at least for tetracyclines and sulfonamides including dapsone. Thirthy-six laboratories 
subscribed for participation in the proficiency study but for one of them it was not possible to get the 
samples through customs. Within the timeframe of the study 35 laboratories submitted results: 34 
laboratories submitted results for the screening analysis and 27 for the quantitative confirmatory part.  
 
Three laboratories (labs 2, 19, 26) did not detect any antibiotics using their screening methodology. 
Seventeen laboratories (labs 3, 4, 5, 9, 11, 12, 15, 16, 18, 21, 23, 25, 28, 30, 34, 35 and 37) 
characterized all three samples correctly (compliant or suspect) based on the screening analysis and of 
these fourteen laboratories (3, 4, 5, 11, 12, 15, 16, 18, 21, 25, 28, 30, 35 and 37) indicated the correct 
compound groups for all samples.  
 
The false positive and false negative rate were determined for all the individual laboratories and for all 
individual methods applied. A result is considered to be a false negative result if an antibiotic 
group/compound present in the sample is not detected. When evaluating the results for the individual 
labs (that in some cases carried out several different methods) fifteen false positive results out of 102 
results occurred and twenty-one false negative results out of 64 results occurred.  
 
After evaluating the results for all individual methods applied it became clear that the majority of false 
negative results was caused by using microbiological methods and the failure to detect 
sulfachloropyridazine in targeted instrumental screening methods. An overview of the screening 
analysis results evaluated on basis of all individual methods applied is presented in table 1. Dapson was 
left out of the calculations, because it was not found in any of the screening analyses.  
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If each method is considered separately, the false negative rate for the microbiological methods is 38%, 
for biochemical methods this is 25%, both caused by the Charm II test, and for instrumental analysis 
this is 23% all caused by missing sulfachloropyridazine. The proficiency test of 2009 organised by 
RIKILT included macrolides, quinolones and aminoglycosides in bovine muscle. The test of 2009 
organised by RIKILT showed a false positive rate of 7%, in 2010 this is 15%.  
 
 
Regarding the applied methods it is concluded that: 
 many combinations of screening tests are used to cover the broad range of antibiotic groups; 
 many false negative results are obtained, especially for microbiological screening methods. 
 all false negative results obtained by instrumental methods can be explained by not including 
sulfachloropyridazine in the method. 
Table 1: Overview of correct, false negative and false positive results for microbiological, biochemical and 
instrumental screening methods. 
Material A B C 
False positives 7 4 7 
Microbiology methods 7 3 4 
Biochemical methods 0 1 0 
Instrumental methods 0 0 3 
  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
No. of methods applied 
for the compound 
groups included* 
 38 37 37 
Correct results 41 29 30 23 
Microbiology methods  14 9 9 
Biochemical methods  3 3 3 
Instrumental methods  12 18 11 
False negatives   9 7 14 
Microbiology methods  8 6 6 
Biochemical methods  1 1 1 
Instrumental methods  0 0 7 
* Because some laboratories applied several different methods and some laboratories do not have all compounds relevant for 
this proficiency test included in their method, this number is different from the number of laboratories. 
 
Twenty-five laboratories carried out a quantitative and confirmatory analysis for tetracyclines and 
twenty-seven for sulfonamides including dapsone. Twenty-seven labs included sulfadimidine in their 
quantitative/confirmatory method, 19 labs included sulfachloropyridazine and 16 labs included dapson. 
False negatives occurred during the confirmatory analysis due to the absence of sulfachloropyridazine 
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and/or dapson in the method. One laboratory detected 63 µg/kg sulfaclozin which is considered as a 
false positive result.  
 
For the quantitive analysis of oxytetracycline 20 out of 25 laboratories (80%) obtained satisfactory 
results. For sulfadimidine this was 26 out of 27 laboratories (96%), for sulfachloropyridazine 17 out of 
18 (94%) and for dapsone 12 out of 13 (92%).  
 
Based on the results of this proficiency test it is concluded that: 
 considering the high percentage of false negative results, effort is needed to improve the 
effectiveness for the screening of veterinary drugs in muscle samples; 
 microbiological screening methods relatively often cause false positive results 
 for effectively applying targeted instrumental screening methods (LC-MS/MS or LC-UV) effort is 
needed to include a wider range of compounds; 
 the quantification of especially oxytetracycline is not satisfactory for some laboratories. 
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1 Introduction 
1.1 Proficiency testing 
Proficiency testing is conducted to provide laboratories with a powerful tool to evaluate and 
demonstrate the reliability of the data that is produced. Next to validation and accreditation, proficiency 
testing is an important requirement of the EU Additional Measures Directive 93/99/EEC [1] and is 
demanded by ISO 17025:2005 [2].  
 
The aim of this proficiency study was to give laboratories the possibility to evaluate or demonstrate 
their competence for the analysis of antibiotics in bovine muscle, including the screening analysis. This 
study also provided an evaluation of the methods applied for screening and quantitative confirmatory 
analysis of antibiotics in bovine muscle.  
 
This proficiency study was conducted in accordance with guidelines ISO/IEC 43-1 [3], ISO/IEC 43-2 
[4] and ILAC-G13 [5]. The preparation of the materials, including the suitability testing of the materials 
and the evaluation of the quantitative results were carried out under accreditation by Rikilt - Institute of 
Food Safety. 
1.2 Previous results 
In2009 Rikilt organized a proficiency test that focused on both the screening and confirmation part of 
antibiotic analysis in muscle focussing on flumequine, lincomysin and spectinomycin. Results showed 
that a huge effort was needed to improve the effectiveness of the screening of antibiotics in muscle 
samples. In the 2009 proficiency test, only fifteen out of twenty-six laboratories screened the samples 
correctly (compliant or suspect) and only three labs indicated the correct compound groups for all 
samples. 
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2 Test materials 
This proficiency study focused on oxytetracycline (a tetracycline) and the combination of sulfadimidine 
(also called sulfamethazine or sulfadimerazine), sulfachloropyridazine (both sulfonamides) and dapson 
(a compound closely related to sulfonamides). The maximum residue limits (MRLs) for these 
compounds in bovine muscle are presented in table 2; dapson is a banned substance [14]. 
Table 2: MRL in bovine muscle of the compounds included in the proficiency test [6]. 
Compound MRL in bovine musle (µg/kg) 
Oxytetracycline 100 
Sulfadimidine 100 
Sulfachloropyridazine 100 
Dapson - 
2.1 Sample preparation 
One blank material (A), one material (B) containing oxytetracycline (OTC) and one material (C) 
containing a combination of sulfadimidine (SDD), sulfachloropyridazine (SCP) and dapson (DAP) were 
prepared. Material B and C were prepared by adding methanolic solutions of the selected compounds to 
blank bovine muscle aiming at the levels as presented in table 3. Each of the materials was 
homogenized under cryogenic conditions according to in-house standard operating procedures [15]. 
Table 3: Target amount of antibiotics in the proficiency test materials.  
Target amount (µg/kg)  
Material code 
OTC SDD SCP DAP 
A - -  - 
B 120 -  - 
C - 120 90 5 
2.2 Sample identification 
After homogenization, the sample materials were divided in subportions and stored in polypropylene 
containers. Each contained contained at least 50 gram of sample, yielding a total of 51 containers of 
material A and 113 containers of both material B and C. The samples for the participants were randomly 
selected and coded from AB1/2010/MUSCLE/001 through 135. For each laboratory a sample set was 
prepared consisting of one randomly selected sample of material A, B and C. The codes of the samples 
belonging to each sample set are presented in Annex 1.The remaining samples were used for 
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homogeneity and stability testing. For homogeneity and stability testing, 20 randomly selected 
containers of material B and C were assigned [15]. 
2.3 Participants 
Thirty-six laboratories subscribed for participation in the proficiency study of which 30 are situated 
within Europe. One lab, situated outside Europe, did not get the samples through customs and was thus 
unable to participate. 
2.4  Sample distribution and instructions 
Each of the participating laboratories received a randomly assigned laboratory code (1 through 37). The 
sample sets with the corresponding number, consisting of three coded samples (Annex 1) were sent to 
the participating laboratories on May 5th, 2010. The sample sets were packed in an insulating box 
containing dry ice or cool packs and were dispatched to the participants immediately by courier. One 
laboratory reported that the samples were not sufficiently frozen at arrival. New samples were sent to 
this laboratory. The samples of two labs were returned to RIKILT after two days without a reason, so 
new sample sets were sent to these laboratories.  
Finally all laboratories confirmed the receipt of the samples in good condition. The samples were 
accompanied by a letter (Annex 3) describing the requested screening analyses, an acknowledgement of 
receipt form and a screening results form. Three labs asked for additional sample material for the 
confirmatory analysis. 
 
The laboratories were asked to store the samples until analysis according to their own laboratory’s 
procedure. A single analysis of each sample was requested, resulting in one result for each material A, B 
and C. The deadline for sending in the screening results was May 29th 2010, allowing the participants 3 
weeks for screening analysis. After the screening results were returned, the participants received new 
instructions for the quantitative confirmatory analysis (Annex 4). The deadline for the confirmatory 
analysis was August 1st 2010. 
2.5 Homogeneity study 
The homogeneity of the materials was tested according to The International Harmonized Protocol for 
Proficiency Testing of Analytical Laboratories [7] and ISO 13528 [8], taking into account the insights 
discussed by Thompson [9] regarding the Horwitz equation. With this procedure the between-sample 
standard deviation ( ss ) and the within-sample standard deviation (sw) are compared with the target 
standard deviation derived from the Horwitz equation ( Hσ , §4.2.3). The method applied for 
homogeneity testing is considered suitable if Hws 5.0? and a material is considered adequately 
homogeneous if Hs σ3.0s ? .  
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Ten containers of materials B were analyzed in duplicate for oxytetracycline and ten containers of 
sample C were analyzed in duplicate for sulfadimidine, sulfachloropyridazine and dapson to determine 
the homogeneity of the materials. The results of the homogeneity study and their statistical evaluation 
are presented in Annex 2a through d. All materials demonstrated to be sufficiently homogeneous for use 
in the proficiency study.  
 
No extensive homogeneity study was carried out for material A. The homogeneity of this material is not 
relevant because the results of these materials will not be evaluated in a quantitative way. Furthermore, 
it is assumed that the homogeneity of material A is comparable to the homogeneity of the other 
materials because all materials are homogenized in the same way. Nevertheless, three randomly selected 
samples of material A were analyzed for tetracyclines and sulfonamides. None of these antibiotics were 
detected. It was concluded that material A is suitable to use in the proficiency study. 
2.6 Stability 
Just after preparation of the materials six randomly selected samples of each material were stored at  
<-70 °C. It is assumed that the antibiotics included in this proficiency test are stable at these storage 
conditions. The remaining samples were stored at -20 °C. Of these, six at random selected samples were 
subjected to a thaw-freeze cycle to verify if thawing and freezing samples, as is likely to occur when 
a screening and confirmatory analysis is carried out, does not affect the stability.  
 
On May 7th two sets of six samples were selected and stored at <-70°C. In the morning of September 8th 
two sets of six samples were selected from the samples stored at -20°C and thawed. After four hours at 
room temperature these samples were again stored at -20°C. On September 22nd, 138 days after 
preparation of the samples, six samples that had been stored at -20°C, six samples that were subjected to 
a thaw-freeze cycle and six samples that had been stored at <-70°C were analyzed for oxytetracycline. 
On September 24th, 140 days after preparation of the samples, a similar procedure was applied 
sulfadimidine, sulfachloropyridazine and dapsone. For each set of samples, the average of the results 
and the standard deviation was calculated.  
 
First it was determined if a consequential instability occurred [7, 8]. A consequential instability occurs 
when the average value of the samples stored at -20°C or the samples subjected to the thaw-freeze cycle 
is more than 0.3σH below the average value of the samples stored at <-70 °C. If so, the instability has a 
significant influence on the calculated z-scores. Second, it was determined if a statistically significant 
instability occurred using a Students t-test [8]. The results and statistical evaluation of the stability test 
are presented in Annex 5.  
 
For oxytetracycline and sulfadimidine no consequential nor a statistical significant difference was 
observed between the samples stored at <-70°C, the samples stored at -20°C and the samples that were 
subjected to a thaw-freeze cycle. The samples are considered sufficiently stable.  
 
For sulfachloropyridazine and dapson no consequential nor a statistical significant difference was 
observed between the samples stored at <-70°C and the samples stored at -20°C. However, a 
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consequential and a statistical difference were observed between the samples stored at <-70°C and the 
samples subjected to a thaw-freeze cycle. For both compounds the thaw-freeze cycle resulted in an 
average that is below the average of the samples stored at <-70°C. Therefore, for sulfachloropyridazine 
and dapson the observed instability is incorporated in the calculation of the za-scores (§4.2.4).  
 RIKILT Report 2010.010 14 
3 Applied methods of analysis 
The participating laboratories applied biological, biochemical or instrumental methods or a combination 
of these methods for screening analysis. An overview of applied screening methods is presented in 
Annex 6. Seventeen laboratories applied a microbiological plate test ranging from four to twelve plates 
among which two laboratories applied the EU plate test, eight laboratories used the EU 4 plate test with 
an additional plate for quinolones and/or tetracyclines, two laboratories applied the Nouws Antibiotic 
Test (NAT) and two applied the STAR test. Five laboratories applied the Premi®test (three with a 
preceding solvent extraction) either or not in combination with other microbiological, biochemical or 
instrumental methods.  
Seven laboratories applied biochemical methods (Charm II, Tetrasensor, SPR, RIA, ELISA, beta-
STAR) and twenty laboratories applied an instrumental method (LC-MS/MS, LC-ToF/MS, LC-FLD, 
TLC, LC-UV, HPTLC or LC-DAD) for the screening analysis. 
 
Twenty-seven laboratories carried out one or more confirmatory analyses. The substance groups for 
which a confirmatory analysis was carried out were selected based on the screening results and on 
additional information that was given to the participants (Annex 4) after the screening analyses. An 
overview of the quantitative confirmatory methods applied and the compounds included in the methods 
is presented in Annex 7. 
 
For the quantitative and confirmatory analysis of tetracyclines in bovine muscle several different 
methods are applied. An overview of the applied confirmatory analyses for oxytetracycline is presented 
in Annex 7b. For the analysis of oxytetracycline in bovine muscle tissue many different extraction 
solvents or mixtures of solvents were used. For the sample clean up also several different techniques 
were applied: sixteen laboratories applied solid phase extraction using phases based on C18 , cyclohexyl 
or polymers. One laboratory used liquid-liquid extraction to clean up their raw extract. The other 
laboratories only filtered/diluted/evaporated their extract before injection. Several detection techniques 
were applied for the quantitative analysis of oxytetracycline in bovine muscle: four laboratories applied 
LC combined with diode array detection (DAD), seventeen laboratories used MS/MS as the detection 
technique and one laboratory combined LC-FLU and LC-MS/MS, one combined LC-Orbitrap and LC-
MS/MS and one combined LC-UV and LC-DAD. 
 
Of the participants that used mass spectrometric or DAD detection, eleven used an internal standard for 
the quantification of oxytetracycline. The internal standards used are: 
 Demeclocycline (demethylchlortetraycline); 
 Methacycline; 
 4-Epi-demethylchlortetracycline; 
 Ciprofloxacin-d8 
 
For the quantitative and confirmatory analysis of sulfonamides including dapson in bovine muscle 
several different methods are applied. An overview of the applied quantitative confirmatory methods is 
presented in Annex 7c. One lab used a specific method for dapson. 
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For the analysis of sulfonamides including dapson in bovine muscle tissue many different extraction 
solvents or mixtures of solvents were used. For the sample clean up also several different techniques 
were applied: nine laboratories applied solid phase extraction using phases based on silica, cation 
exchange or polymers. Other laboratories used liquid-liquid extractions, filtration, dilution or 
evaporation of the extraction solvent to clean up their raw extract. Several detection techniques were 
applied for the quantitative analysis of sulfonamides including dapson in bovine muscle: two 
laboratories applied LC combined with UV detection, twenty laboratories used MS/MS as the detection 
technique and one laboratory applied LC-FLU. One lab combined LC-Orbitrap and LC-MS/MS and one 
lab combined LC-DAD and LC-MS/MS. 
 
Of the participants that used mass spectrometric or FLU detection, eighteen used an internal standard 
for the quantification of sulfonamides and dapsone. The internal standards used are: 
 Sulfadiazine-13C6; 
 Sulfadimidine-13C6 or d4 or d7; 
 Sulfanilamide-13C6 
 Sulfadimethoxine-d6 
 Sulfachloropyridazine-13C6; 
 Dapson-d8; 
 Sulfadiazine-d4 or 13C6; 
 Sulfadoxine-d3; 
 Sulfapyridine; 
 Sulfaphenazole; 
 Sulfadimidine-13C, 3-aminophenylsulfone; 
 Sulfamethoxazole-13C6; 
 Sulfameter; 
 Sulfachloropyridazine; 
 Ciprofloxacin-d8; 
 Sulfathiazole-13C6. 
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4 Statistical evaluation 
The evaluation of the screening and quantitative analysis are carried out separately. The screening 
analysis is evaluated in a qualitative way resulting in a false negative and false positive rate [10]. The 
statistical evaluation of the quantitative part of the study was carried out according to the International 
Harmonized Protocol for the Proficiency Testing of Analytical Laboratories [7], elaborated by ISO, 
IUPAC and AOAC and ISO 13528 [8] in combination with the insights published by the Analytical 
Methods Committee [11, 12] regarding robust statistics. 
4.1 Screening analysis 
First, all laboratories were evaluated separately regarding the screening results in which the number of 
false positives and false negatives is determined for each laboratory. The number of false positives is the 
number of samples in which growth inhibition or an antibiotic was detected although no antibiotic was 
present. A result is assigned as false negative if an antibiotic present is not detected although it is added 
to the bovine muscle. 
After the individual evaluation of the laboratories an overall evaluation was carried out. In this the 
overall false positive and false negative rates were calculated for all laboratories that submitted results 
for the screening analysis [10]. Next it was studied if any relation exists between false negatives 
occurring and applied screening methods. 
4.2 Quantitative analysis 
For the evaluation of the quantitative results the assigend value, the uncertainty of the assigned value, 
a target standard deviation and z-scores were calculated.  
4.2.1 Calculation of the assigned value 
The assigned value (X) was determined using robust statistics [8,11,12]. The advantage of robust 
statistics is that all values are taken into account: outlying observations are retained, but given less 
weight. Furthermore, it is not expected to receive normally distributed data in a proficiency test. When 
using robust statistics, the data does not have to be normally distributed in contrast to conventional 
outlier elimination methods. 
The robust mean of the reported results of all participants, calculated from an iterative process that starts 
at the median of the reported results using a cut-off value depending on the number of results, was used 
as the assigned value [8,11]. The assigned value is therefore a consensus value. 
4.2.2 Calculation of the uncertainty of the assigned value 
The uncertainty of the assigned value is calculated to determine the influence of this uncertainty on the 
evaluation of the laboratories. A high uncertainty of the assigned value will lead to a high uncertainty of 
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the calculated participants za-scores. If the uncertainty of the assigned value and thus the uncertainty of 
the za-score is high, the evaluation could indicate unsatisfactory method performance without any cause 
within the laboratory. In other words, illegitimate conclusions could be drawn regarding the 
performance of the participating laboratories from the calculated za-scores if the uncertainty of the 
assigned value is not taken into account. 
The uncertainty of the assigned value (the robust mean) is calculated from the estimation of the standard 
deviation of the assigned value and the number of values used for the calculation of the assigned value: 
 
n
σˆ
u =  
 
where: 
u = uncertainty of the assigned value;  
n = number of values used to calculate the assigned value;  
σˆ = the estimate of the standard deviation of the assigned value resulting from robust statistics. 
 
According to ISO 13528 [8] the uncertainty of the assigned value (u) is negligible and therefore does 
not have to be included in the statistical evaluation if: 
 
pσ3,0u?  
 
where: 
u  = the uncertainty of the assigned value; 
p
σ  = target standard deviation (§ 4.2.3). 
 
In case the uncertainty of the assigned value does not comply with this criterion, the uncertainty of the 
assigned value should be taken into account when evaluating the performance of the participants 
regarding the accuracy (§ 4.2.4). 
4.2.3 Calculation of the target standard deviation 
According to Commission Decision 2002/657/EC [13], the coefficient of variation for the repeated 
analysis of a reference or fortified material under reproducibility conditions, shall not exceed the level 
calculated by the Horwitz equation. The Horwitz equation, 8495.0H c02.0σ = , presents a useful and 
widespread applied relation between the expected standard deviation of a singular analysis result under 
reproducibility conditions, Hσ and the concentration, c (g/g). It expresses inter-laboratory precision 
expected in inter-laboratory trials. Therefore, this relation is suitable for calculating the target standard 
deviation, pσ in proficiency tests. 
 
Thompson [7] demonstrated that the Horwitz equation is not applicable to the lower concentration range 
(<120 µg/kg) as well as to the higher concentration range (>138 g/kg). Therefore a complementary 
model is suggested: 
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For analyte concentrations <120 µg/kg: 
c22.0σ H =  
 
For analyte concentrations >138 g/kg: 
5.0
H c01.0σ =  
 
where: 
Hσ  = expected standard deviation in inter-laboratory trials; 
c   = concentration of the analyte (g/g). 
  
The target standard deviation ( pσ ) of oxytetracycline was determined using the regular Horwitz 
equation. In this calculation c = the assigned value (X) expressed in g/g and pH σσ = . 
4.2.4 Performance characteristics with regard to the accuracy 
For illustrating the performance of the participating laboratories with regard to the accuracy a za-score is 
calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO/IEC Guide 
43-1 [3] and ISO 13528 [8] are applied. According to these guidelines za-scores are classified as 
presented in table 4.  
Table 4: Classification of za-scores. 
|z|  2 Satisfactory 
2 < |z| < 3 Questionable 
 |z|  3 Unsatisfactory 
 
If the calculated uncertainty of the assigned value complies with the criterion mentioned in §4.2.2, the 
uncertainty is negligible. In this case the accuracy z-score is calculated from: 
 
p
a σ
Xx
z
-
=    Equation I 
 
where: 
az  = accuracy z-score; 
x  = the average result of the laboratory; 
X  = assigned value; 
pσ  = target standard deviation. 
 
However, if the uncertainty of the assigned value does not comply with the criterion mentioned in § 
4.2.2, it could influence the evaluation of the laboratories. Therefore in that case, the uncertainty is 
taken into account by calculating the accuracy z-score [8]: 
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22
-'
u
Xxz
p
a     Equation II 
 
where: 
a'z  = accuracy z-score taking into account the uncertainty of the assigned value; 
x  = the average result of the laboratory; 
X   = assigned value; 
pσ  = target standard deviation; 
u   = uncertainty of the assigned value. 
 
If a consequential instability of the proficiency test materials is observed, this can influence the 
evaluation of the laboratory performance. Therefore, in that case the consequential instability should be 
taken into account when calculating z-scores. Because instability only regards one side of the 
confidence interval (in most cases a decrease of the amount is expected) this correction only applies to 
the lower 2s limit and results in an asymmetrical confidence interval.  
 
In the case of a consequential instability the accuracy z-score for the laboratories that reported an 
amount below the assigned value is corrected for this instability by: 
 
-
=
+
ai 2 2
p
x X
z
σ Δ
  Equation III  
where: 
aiz  = accuracy z-score taking into account the instability of the assigned value; 
x  = the average result of the laboratory; 
X   = assigned value; 
pσ  = target standard deviation; 
Δ  = difference between average concentration of compound stored at -70°C and average 
concentration after thaw-freeze cycle. 
 
In some cases the uncertainty of the assigned value does not comply with the criterion in §4.2.4 ánd a 
consequential instability is observed. In this case the z'a score for the laboratories that reported an 
amount below the assigned value is corrected for this instability by: 
 
-
=
+ +
ai 2 2 2
p
x X
z'
σ Δ u
  Equation IV 
 
where: 
aiz'  = accuracy z-score taking into account the uncertainty and instability of the assigned value; 
x  = the average result of the laboratory; 
X  = assigned value; 
pσ  = target standard deviation; 
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Δ  = difference between average concentration of compound stored at -70°C and average 
concentration after thaw-freeze cycle; 
u  = uncertainty of the assigned value. 
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5 Results and discussion 
Thirty-six laboratories subscribed for the participation in the proficiency test for antibiotics in bovine 
muscle. Of these laboratories, 34 carried out a screening analysis and 27 carried out at least one 
confirmatory analysis (Table 5). For laboratories that carried out a screening and a confirmatory 
analysis the choice of the applied confirmatory analysis was based on the screening analysis results 
together with the additional information that was sent to the participants after reporting the screening 
analyses. The confirmation instructions (Annex 4) contained all compound groups found in the 
screening analyses plus tetracyclines and sulfonamides including dapson (if not reported in the 
screening results yet). 
Table 5: Number of laboratories that reported results for each analysis. 
Analysis Compound No. of labs that reported a result 
Screening  34 
Total 27 
Oxytetracycline 25 
Sulfadimidine 27 
Sulfachloropyridazine 18 
Quantitative / confirmatory 
Dapson 13 
5.1 Evaluation of the screening analysis 
In the ideal case each laboratory that carried out a screening analysis would find the sample of material 
A compliant, the sample of material B and C suspect (for tetracyclines/OTC and 
sulfonamides/sulfadimidine, sulfachloropyridazine and dapson respectively). The actual screening 
results are presented in Annex 8a. 
 
In this proficiency test for the screening analysis fifteen false positive results out of 102 results 
occurred, based on the overall results of materials A, B and C. Twenty-one false negative results out of 
64 results occurred, based on the final results of materials B and C, which is caused by using 
microbiological methods and the failure to detect sulfachloropyridazine in targeted instrumental 
screening methods. 
 
For material B, out of the 32 laboratories that screened for the presence for tetracyclines, 25 reported 
material B as a suspect sample for tetracyclines, oxytetracycline or a growth inhibitor (22% false 
negative). For material C, out of the 32 laboratories that screened for the presence of sulfonamides, 25 
reported material C as a suspect sample for sulfonamides, sulfadimidine and/or sulfachloropyridazine or 
a growth inhibitor (22% false negative). However, when the failure to detect sulfachloropyridazine is 
taken into account, 18 out of 32 (44% false negative) laboratories correctly screened this material. 
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For the microbiological methods the false negative rate is highest with 38%. For biochemical methods 
the false negative rate is 25% and for instrumental screening methods 23%, the latter entirely caused by 
failure to detect sulfachloropyridazine. 
 
For oxytetracycline, the false negative results were caused by using the EU 4 plate test (labs 2, 19, 20, 
26 and 32), the STAR test (lab 7), the Charm II test (lab 12), a B. cereus pH=6 plate (lab 32) and the 
Premi®test without solvent extraction (lab 13). It stands out that the B. subtilis plate at pH=6 in this 
method is not suited for the screening of bovine muscle for the presence of tetracyclines at relevant 
levels. Including a B. cereus plate at pH=6-6.5 is an often applied strategy to fix this deficiency and 
appears to be effective; only 2 (labs 7 and 32) out of the 11 laboratories applying this bacterium, 
reported a false-negative result.  
 
Five labs used the Premi®test as a screening method. The results of this method are somewhat 
ambiguous. The three labs that applied a solvent extraction prior to the Premi®test, to enhance the 
sensitivity of the test, all reported growth inhibition for material B, however, two of them also reported 
growth inhibition for the blank material A. Of the two labs that used Premi-test without solvent 
extraction, one reported a positive result and the other a negative result for material B, while both found 
material A negative. 
 
It is concluded that instrumental methods (12 labs), Tetrasensor (2 labs) and the B. cereus pH=6-6.5 
plate (11 labs, 9 correct results) are suited for screening of oxytetracycline in bovine muscle at relevant 
levels. Concerning the B. cereus based microbiological methods it may also be assumed that this result 
implies that the test will also be capable to detect the other veterinarily relevant tetracyclines, since 
oxytetracycline is considered to be the least detectable compound in this antibiotic group. Conclusions 
considering the suitability of the Charm II test for detection of tetracyclines remain uncertain, since only 
one of the two laboratories using the test reported a positive result. 
 
For sulfonamides, it should be concluded that most of the applied microbiological methods are not 
capable of effectively detecting this antibiotic group at relevant levels. The only microbial plate test 
which appears sensitive enough for screening of sulfonamides is the B. pumilis at pH=7 +TMP (used by 
labs 23 and 36). Additionally, all five laboratories using Premi-test reported growth inhibition for 
material C, though as mentioned above, two of them also reported false positive results for material A. 
It stands out that many laboratories have already recognized the problematic microbial detection of 
sulfonamides, since 9 out of 22 laboratories that use microbial screening methods, have implemented 
alternative screening methods for sulfonamides, like TLC, LC-MS/MS, SPR, Charm II, HPLC. 
 
In general it can be concluded that most of these methods appear suitable. Two laboratories that used 
LC-UV or HPTLC reported sulfaclozine and sulfaquinoxaline respectively, which are false positive 
results. Analogous to tetracyclines, suitability of the Charm II test for detection of sulfonamides also 
remains unclear, since also with material C only one of the two laboratories using this test reported a 
positive result. Seven laboratories that used an instrumental screening method missed the presence of 
sulfachloropyridazine, all because the compound is not included in the method. All laboratories 
reporting individual compounds, reported the presence of sulfadimidine. For screening analysis using 
targeted methods it is evidently of importance that all relevant compounds are included.  
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5.2 Evaluation of the quantitative analysis 
Twenty-seven laboratories carried out one or more quantitative confirmatory analyses. An overview of 
the compounds found in the samples is presented in Annex 9a. Annex 9b gives an overview of false 
positive results that occurred during the quantitative analysis. One laboratory (lab 9) reported 
sulfaclozine with an amount of 63 µg/kg in the sample belonging to material C. Sulfaclozine only 
differs from sulfachloropyridazine in the position of the N-atom (ortho or para). 
This is considered as a false positive result. False negatives only occurred in material C, caused by the 
exclusion of sulfachloropyridazine and/or dapson in the instrumental method. Nine laboratories missed 
the presence of sulfachloropyridazine and fourteen laboratories missed the presence of dapson. 
 
Twenty-five laboratories carried out a quantitative confirmatory analysis for tetracyclines. All of these 
laboratories confirmed the presence of oxytetracycline and reported a quantitative result (Annex 10). 
The lowest value reported is 83.8 µg/kg and the highest value is 247.5 µg/kg. The assigned value of 
oxytetracycline is 122.0 µg/kg with a robust standard deviation of 30.1 µg/kg expressing the 
reproducibility within this proficiency test. This is very much comparable to the value suggested by 
Horwitz: 26.8 µg/kg. The uncertainty of the assigned value is 6.0 µg/kg which does not exceed 0.3p 
(§4.2.2) and no consequential instability was observed (§4.2.4). Therefore za-scores were calculated 
(Annex 10, a graphical representation of the za-scores is included). With respect to the accuracy two 
results were questionable and three were unsatisfactory (Table 4).  
 
Twenty-seven laboratories carried out a quantitative confirmatory analysis for sulfonamides. All of 
these laboratories confirmed the presence of sulfadimidine and reported a quantitative result (Annex 
11). The lowest value reported is 33 µg/kg and the highest value is 125 µg/kg. The assigned value of 
sulfadimidine is 90.1 µg/kg with a robust standard deviation of 16.9 µg/kg expressing the 
reproducibility within this proficiency test. This is very much comparable to the value suggested by 
Horwitz: 19.8 µg/kg. The uncertainty of the assigned value is 3.3 µg/kg which does not exceed 0.3p 
(§4.2.2) and no consequential instability was observed (§4.2.4). Therefore za-scores were calculated 
(Annex 11, a graphical representation of the za-scores is included). With respect to the accuracy all but 
one results are satisfactory. The deviating result is questionable (Table 4). 
 
Of the twenty-seven laboratories that carried out a quantitative confirmatory analysis for sulfonamides, 
nineteen laboratories included sulfachloropyridazine in their confirmatory method (Annex 12). All but 
one laboratories confirmed the presence of sulfachloropyridazine. The lowest value reported is 18 µg/kg 
and the highest value is 89 µg/kg. The assigned value of sulfachloropyridazine is 64.3 µg/kg with a 
robust standard deviation of 14.8 µg/kg expressing the reproducibility within this proficiency test. This 
is very much comparable to the value suggested by Horwitz: 14.1 µg/kg. The uncertainty of the 
assigned value is 3.5 µg/kg which does not exceed 0.3p (§4.2.2). Therefore the uncertainty of the 
assigned value is not taken into account in the evaluation of the laboratories. However, a consequential 
instability was observed caused by the thaw-freeze cycle and thus the instability observed was taken 
into account by calculating zai-scores (Annex 12, a graphical representation of the zai-scores is included). 
With respect to the accuracy all but one results are satisfactory. The deviating result is questionable 
(Table 4). 
 
Sixteen labs included dapson in their confirmatory method and thirteen laboratories reported a 
quantitative confirmatory analysis for dapson (Annex 13). The lowest value reported is 1.42 µg/kg and 
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the highest value is 4.8 µg/kg. The assigned value of dapson is 3.35 µg/kg with a robust standard 
deviation of 1.0 µg/kg expressing the reproducibility within this proficiency test. This is very much 
comparable to the value suggested by Horwitz: 0.74 µg/kg. The uncertainty of the assigned value is 
0.29 µg/kg which does exceed 0.3p (§4.2.2). Therefore the uncertainty of the assigned value is taken 
into account in the evaluation of the laboratories. Furthermore a consequential instability was observed 
caused by the thaw-freeze cycle and thus also the instability observed was taken into account calculating 
z'ai-scores (Annex 13, a graphical representation of the z'ai-scores is included). With respect to the 
accuracy all but one results are satisfactory. This result is questionable. 
 
In general it can be concluded that most of the quantitative methods used are suitable for quantification 
of sulfadimine, sulfachloropyridazine and dapson. However, the quantification of oxytetracycline is 
more difficult, since 5 labs obtained z-scores > 2 . Furthermore, it is important to include a wider range 
of compounds in the instrumental methods to avoid false negative results. 
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6 Conclusions 
Thirty-five laboratories reported results for the proficiency study of antibiotics in bovine muscle. Out of 
these three laboratories (labs 16, 21 and 35) showed optimal performance by screening/detecting all 
compounds, the absence of false positives and false negatives and a correct quantification of 
oxytetracycline, sulfadimidine, sulfachloropyridazine and dapson. Lab 16 used the Premi-test and LC-
MS/MS for the screening part. Lab 21 used SPR and 6 microbiological plates (EU 4 pt + E. coli at pH=8 
and B. cereus at pH=6) for the screening part. Lab 35 used LC-MS/MS for the screening of the samples. 
Three other laboratories (labs 10, 27 and 36) also quantified/confirmed all 4 compounds correctly, but 
reported false positive (10 and 36) or false negative (10 and 27) screening results. 
 
The proficiency test of 2009 organised by RIKILT discussed macrolides, quinolones and 
aminoglycosides in bovine muscle. The test of 2009 showed a false negative rate of 53%, which is 33% 
in 2010. The false positive rate was 7% in 2009, which is 15% in 2010. For microbiological methods the 
overall false negative rate was 73% in 2009, which is 38% in 2010. For biochemical it was 50% and is 
25% in 2010 and for instrumental methods it was 22% and is 23% in 2010.  
 
For the microbiological methods the false negative rate is 38%, for biochemical tests this is 25% and for 
instrumental methods this is 23%. The false negative rate for microbiological methods is mainly caused 
by applying the EU four plate test, which relies on a B. subtilis plate at pH=6 for the screening of 
tetracyclines (assigned value of 122.0 µg/kg oxytetracycline) and a B. subtilis (+TMP) plate at pH=7.2 
for sulfonamides (assigned values of 90.1 µg/kg sulfadimine and 64.3 µg/kg sulfachloropyridazine) . 
The false negative rate for biochemical methods is caused by using the Charm II test. The false negative 
rate for instrumental methods is caused by the use of methods in which sulfachloropyridazine is not 
included. 
 
For the quantitative and confirmatory analysis 25 laboratories reported results for oxytetracycline, 27 
for sulfadimidine, 18 for sulfachloropyridazine and 13 for dapson. For oxytetracycline 20 out of 25 
laboratories obtained satisfactory results. For sulfadimidine 26 out of 27 laboratories obtained a 
satisfactory result, for sulfachloropyridazine this is 17 out of 18 and for dapson 12 out of 13. One false 
positive result and four false negatives were reported although the specific compounds 
(sulfachloropyridazine and/or dapson) were included in the method. Eighteen laboratories did not detect 
sulfachloropyridazine and/or dapsone because they were not included in the method. 
 
Based on the results of this proficiency test it is concluded that: 
 especially the screening part of the proficiency test demonstrates the drawbacks in the analytical 
approach for the analysis of antibiotics in muscle samples; 
 considering the high percentage of false negative results, effort is needed to improve the 
effectiveness for the screening of veterinary drugs in muscle samples; 
 microbiological screening methods relatively often cause false positive results 
 the EU 4 plate test is not suited for the screening of oxytetracycline, sulfadimidine and 
sulfachloropyridazine in bovine muscle at relevant levels. 
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 for effectively applying targeted instrumental screening methods like LC-MS/MS, effort is needed 
to include a much wider range of compounds. 
 
 RIKILT Report 2010.010 27 
References 
1 Council directive 93/99/EEC of 29 October 1993 on the subject of additional measures concerning the 
official control of foodstuffs. Official Journal L 290, 24/11/1993, 0014 - 0017. 
 
2 ISO/IEC 17025:2005(E). 2005. General Requirements for the Competence of Calibration and Testing 
Laboratories 
 
3 ISO/IEC Guide 43-1. 1997. Proficiency testing by inter-laboratory comparisons - Part 1: Development 
and operation of proficiency testing schemes, 2nd edition. 
 
4 ISO/IEC Guide 43-2. 1997. Proficiency testing by inter-laboratory comparisons - Part 2: Selection and 
use of proficiency testing schemes by laboratory accreditation bodies, 1st edition. 
 
5 ILAC-G13:2007. 2007. ILAC Guidelines for the Requirements for the Competence of Providers of 
Proficiency Testing Scemes. 
 
6 Council Regulation (ECC) No 2377/90. 26 June 1990. Laying down a Community procedure for the 
establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal 
origin. Off. J. Eur. Commun. L224: 1 
 
7 Thompson M, Ellison SL,Wood R. 2006. The International Harmonized Protocol for the Proficiency 
Testing of Analytical Chemistry Laboratories. Pure Appl. Chem. 78(1):145-196. 
 
8 ISO 13528:2005(E). 2005. Statistical methods for use in proficiency testing by inter-laboratory 
comparison, 1st edition. 
 
9 Thompson M. 2000. Recent trends in inter-laboratory precision at ppb and sub-ppb concentrations in 
relation to fitness for purpose criteria in proficiency testing. Analyst. 125:385-386. 
 
10 McClure FD. 1990. Design and analysis of qualitative collaborative studies: minimum collaborative 
program. JAOAC Int. 73 (6): 953-960  
 
11 Analytical Methods Committee. 1989. Robust statistics - How not to reject outliers Part 1. Basic 
concepts. Analyst 114:1693-1697.  
 
12 Analytical Methods Committee. 1989. Robust statistics - How not to reject outliers Part 2. Inter-
laboratory trials. Analyst. 114:1699-1702. 
 
13 Commission Decision 2002/657/EC. 12 August 2002. Implementing Council Directive 96/23/EC 
concerning the performance of analytical methods and the interpretation of results. Official Journal. L 
221:67A-76A. 
 
 RIKILT Report 2010.010 28 
14 Council directive 37/2010 of 22 December 2009 on pharmacologically active substances and their 
classification regarding maximum residue limits in foodstuffs of animal origin. Official Journal L 15, 
20/01/2010. 
 
15 RSVA0989 - De bereiding van referentiematerialen en referentiemonsters - RIKILT 
 RIKILT Report 2010.010 29 
Annex 1 Codification of the samples 
Sample set 
no. Material A* Material B* Material C* 
1 044 032 014 
2 021 031 074 
3 005 036 035 
4 071 017 134 
5 088 030 013 
6 053 041 065 
7 048 020 004 
8 010 058 067 
9 007 016 129 
10 026 123 046 
11 028 055 057 
12 018 118 019 
13 037 131 094 
14 085 110 011 
15 003 083 068 
16 053 041 065 
17 006 120 087 
18 023 096 101 
19 029 090 112 
20 073 086 082 
21 126 095 075 
22 102 051 022 
23 039 038 125 
24 063 099 133 
25 121 072 081 
26 008 066 098 
27 108 024 117 
28 042 009 033 
29 104 061 111 
30 113 047 100 
31 106 127 130 
32 052 080 119 
33 093 077 103 
Annex 1 continued Codification of the samples 
 
RIKILT Report 2010.010 30 
Sample set 
no. Material A* Material B* Material C* 
34 045 128 056 
35 084 135 002 
36 043 122 027 
37 062 060 089 
* all sample codes start with AB1/2010/MUSCLE/ 
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Annex 2a Statistical evaluation of homogeneity data of material 
B for oxytetracycline 
 Oxytetracycline (µg/kg) 
Sample No. Replicate 1 Replicate 2 
Hom/B001 124.3 108.5 
Hom/B002 118.0 127.2 
Hom/B003 111.7 122.1 
Hom/B004 * 110.9 
Hom/B005 83.2 112.6 
Hom/B006 115.7 120.3 
Hom/B007 116.1 113.2 
Hom/B008 116.8 116.4 
Hom/B009 123.5 112.7 
Hom/B010 115.9 111.6 
Grand mean 114.77 
Cochran’s test   
C 0.585 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 25.25 
sx 6.88 
sw 9.04 
ss 2.54 
Critical = 
0.3 Hσ  
0.32 
ss < critical? ACCEPTED 
sw < 0.5 Hσ ? ACCEPTED 
*value was 231.9 µg/kg → outlier 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
 RIKILT Report 2010.010 32 
Annex 2b Statistical evaluation of homogeneity data of material 
C for sulfadimidine 
 Sulfadimidine (µg/kg) 
Sample No. Replicate 1 Replicate 2 
Hom/B001 116.5 109.5 
Hom/B002 115.4 116.4 
Hom/B003 109.0 107.4 
Hom/B004 114.2 113.0 
Hom/B005 113.0 114.7 
Hom/B006 116.3 118.9 
Hom/B007 112.0 111.4 
Hom/B008 122.1 109.9 
Hom/B009 100.4 107.5 
Hom/B010 114.5 116.7 
Grand mean 112.9 
Cochran’s test   
C 0.559 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 24.85 
sx 4.13 
sw 3.65 
ss 3.22 
Critical = 
0.3 Hσ  
7.45 
ss < critical? ACCEPTED 
sw < 0.5 Hσ ? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2c Statistical evaluation of homogeneity data of material 
C for sulfachloropyridazine 
 Sulfachloropyridazine (µg/kg) 
Sample No. Replicate 1 Replicate 2 
Hom/B001 86.7 80.0 
Hom/B002 85.3 88.7 
Hom/B003 90.5 86.2 
Hom/B004 80.1 90.2 
Hom/B005 88.1 83.3 
Hom/B006 87.3 89.9 
Hom/B007 78.0 79.0 
Hom/B008 95.8 82.1 
Hom/B009 85.0 81.8 
Hom/B010 89.0 86.8 
Grand mean 85.7 
Cochran’s test   
C 0.460 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 18.85 
sx 3.27 
sw 4.54 
ss 0.62 
Critical = 
0.3 Hσ  
5.66 
ss < critical? ACCEPTED 
sw < 0.5 Hσ ? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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Annex 2d Statistical evaluation of homogeneity data of material 
C for dapson 
 Dapson (µg/kg) 
Sample No. Replicate 1 Replicate 2 
Hom/B001 4.7 4.7 
Hom/B002 4.9 5.0 
Hom/B003 4.5 4.8 
Hom/B004 4.7 4.7 
Hom/B005 5.1 4.4 
Hom/B006 4.8 4.3 
Hom/B007 4.7 5.0 
Hom/B008 4.9 5.3 
Hom/B009 4.9 4.8 
Hom/B010 4.5 5.0 
Grand mean 4.8 
Cochran’s test   
C 0.347 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s = Hσ  Horwitz: 1.05 
sx 0.16 
sw 0.26 
ss 0.00 
Critical = 
0.3 Hσ  
0.32 
ss < critical? ACCEPTED 
sw < 0.5 Hσ ? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation 
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Annex 3 Instruction letter 
 
 
Dear participant, 
 
Thank you very much for your interest in the proficiency study for the analysis of antibiotics in bovine 
muscle. 
  
Hereby I send you a parcel containing three randomly coded samples. Each sample consists of at least 
50 g bovine muscle. The samples may contain one or more analytes belonging to one ore more of the 
following groups (in alphabetical order):  
 
Aminoglycosides Quinolones 
ß-lactams Sulfonamides 
Macrolides Tetracyclins 
 
Please fill out the accompanied ‘acknowledgement of receipt form’ and return it immediately upon 
receipt of the samples, preferably by fax. 
 
Your laboratory code is: 37 
 
 
Return the screening results before May 28th 2010 
 
Instructions: 
- After arrival store the samples according to your laboratory’s procedures.  
- Defrost the samples before analysis and homogenize them according to your laboratory’s 
procedures. 
- Please analyze the samples according to the predefined screening methods mentioned on the 
registration form. The samples should be treated as routine samples.  
- In order to make the sample suitable for methods that use muscle disks, we propose the following: 
Take a few grams of the sample and let it thaw on a (clean) flat surface, press (e.g. with 
the back of a spoon) to a compact layer with a thickness approaching a regular muscle 
disk and take out a sample using your cork borer. To enhance diffusion, add 50 µl of water 
to the artificial disk, after you have placed it on the test plate.  
- Please make use of your own reference standards. Unfortunately RIKILT – Institute of Food Safety, 
cannot supply antibiotic reference standards. 
- Carry out a single analysis for each sample. Please report the screening results before May 28th 
2010. After reporting the screening results instructions will be given on the quantitative and 
confirmatory analysis. 
- Please use the results form for reporting the results. 
 
Please contact me if you have any questions or need any assistance.  
 
Kind regards, 
Ingrid Elbers  
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Annex 4 Confirmation instructions 
 
 
 
Dear participant, 
 
 
Thank you for reporting the screening results. 
Hereby I send you the instructions for the confirmatory and quantitative part of the proficiency test.  
 
 
- Please confirm and quantify all the compounds that are mentioned in the table below: 
 
Sample 000 Antibiotic group(s) 
Sample 000 Antibiotic group(s) 
Sample 000 Antibiotic group(s) 
 
Carry out a single analysis for each sample. Please confirm the identity of any detected residues 
according to 2002/657/EC. 
- The results should be reported before the 1st of August 2010. 
- Please use the result form for reporting the results. 
 
Please contact me if you have any questions or need any assistance.  
 
Kind regards, 
Ingrid Elbers  
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Annex 8a Overview of screening results 
Lab Material A Material B Material C 
2 - - - 
3 - OTC sulfachloropyridazine       sulfadimidine 
4 - tetracyclines sulfonamides 
5 - growth inhibition/ OTC  
growth inhibition/ 
sulfachloropyridazine       
sulfadimidine 
6 - tetracyclines - 
7 ß-lactams macrolides 
ß-lactams 
 macrolides  
quinolones 
ß-lactams 
macrolides 
tetracyclines 
quinolones 
sulfonamides 
9 - not tested sulfaclozine  sulfadimidine  
10 ß-lactams tetracyclines ß-lactams 
11 - OTC sulfadimidine 
12 - tetracyclines 
sulfonamides/ 
sulfachloropyridazine 
sulfadimidine 
13 - - growth inhibition 
14 tetracyclines tetracyclines tetracyclines 
15 - OTC sulfachloropyridazine sulfadimidine 
16 - growth inhibition/ tetracyclines 
growth inhibition/ 
sulfonamides 
17 aminoglycosides tetracyclines sulfonamides 
18 - tetracyclines sulfonamides 
19 - - - 
20 - - sulfonamides 
21 - tetracyclines sulfonamides 
22 growth inhibition growth inhibition/ tetracyclines 
growth inhibition/ 
sulfonamides 
23 - tetracyclines   sulfonamides sulfonamides 
25 - OTC sulfachloropyridazine sulfadimidine 
26 - - - 
27 - tetracyclines - 
Annex 8a continued Overview of screening results 
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Lab Material A Material B Material C 
28 - OTC sulfadimidine 
29 - not tested not tested 
30 - OTC sulfadimidine 
31 - tetracyclines - 
32 - - sulfadimidine 
33 growth inhibition growth inhibition/ tetracyclines 
growth inhibition/ 
sulfonamides 
34 - tetracyclines ß-lactams 
sulfadimidne 
sulfaquinoxaline 
35 - OTC sulfachloropyridazine sulfadimidine 
36 ß-lactams tetracyclines sulfonamides 
37 - OTC sulfadimidine 
- = not detected 
 RIKILT Report 2010.010 51
Annex 8b False positives and false negatives in screening analysis 
False positive results 
Lab code Sample code Material Suspect for 
7 048 A ß-lactams macrolides 
7 020 B 
ß-lactams 
macrolides 
quinolones 
7 004 C 
ß-lactams 
macrolides 
quinolones 
tetracyclines 
9 129 C sulfaclozine 
10 026 A ß-lactams 
10 046 C ß-lactams 
12 019 C ß-lactams 
14 085 A tetracyclines 
14 011 C tetracyclines 
17 006 A aminoglycosides 
22 102 A growth inhibition 
23 038 B sulfonamides 
33 040 A growth inhibition 
34 128 B ß-lactams 
34 056 C sulfaquinoxaline 
36 043 A ß-lactams 
 
Annex 8b continued False positives and false negatives in screening analysis 
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False negative results 
Lab code Sample code Tetracyclines/oxytetracycline Sample code 
Sulfonamides/sulfadimidine and 
sulfachloropyridazine 
2 031 X 074  X 
7 020 X   
9   129 X* 
10   046 X 
11   057 X* 
12 118 X   
13 131 X   
14   011 X 
19 090 X 112 X 
20 086 X   
26 066 X 098 X 
27   117 X 
28   033 X* 
30   100 X* 
31   130 X 
32 080 X 119 X* 
37   089 X* 
X =not detected  
* missed sulfachloropyridazine with LC-MS or LC-UV
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Annex 9a Overview of quantitative/confirmatory results 
Lab Material A Material B Material C 
1  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
4  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
5  no method Sulfadimidine Sulfachloropyridazine 
6  no method Sulfadimidine Sulfachloropyridazine 
9  Oxytetracycline Sulfadimidine 
10  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
11  Oxytetracycline Sulfadimidine 
12  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
14  Oxytetracycline Sulfadimidine 
15  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
16  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
17  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
18  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
19  Oxytetracycline Sulfadimidine 
20  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
21  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
22  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
23  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
25  Oxytetracycline Sulfadimidine Sulfachloropyridazine 
Annex 9a continued Overview of quantitative/confirmatory results 
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Lab Material A Material B Material C 
27  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
28  Oxytetracycline Sulfadimidine Dapson 
30  Oxytetracycline Sulfadimidine Dapson 
32  Oxytetracycline Sulfadimidine 
33  Oxytetracycline Sulfadimidine Dapson 
35  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
36  Oxytetracycline 
Sulfadimidine 
Sulfachloropyridazine 
Dapson 
37  Oxytetracycline Sulfadimidine Dapson 
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Annex 9b False positives and false negatives in 
 quantitative/confirmatory analysis 
False positive results 
Lab code Sample code Material Compound confirmed 
09 129 C Sulfaclozine 
 
False negative results 
Lab code Sample code Material Compound confirmed 
01 014 C Dapson* 
05 013 C Dapson 
06 065 C Dapson 
09 129 C Dapson* 
11 057 C Sulfachloropyridazine Dapson 
14 011 C Sulfachloropyridazine Dapson 
15 068 C Dapson 
17 087 C Dapson* 
18 101 C Dapson 
19 112 C Sulfachloropyridazine Dapson 
20 082 C Dapson 
23 125 C Dapson 
25 081 C Dapson 
28 033 C Sulfachloropyridazine*
30 100 C Sulfachloropyridazine 
32 119 C Sulfachloropyridazine Dapson 
33 103 C Sulfachloropyridazine 
37 089 C Sulfachloropyridazine 
* included in method 
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Annex 10 Results for the analysis of oxytetracycline 
Oxytetracycline 
Assigned value: 122.0 µg/kg 
Uncertainty of assigned value: 6.0 µg/kg 
Target standard deviation (Horwitz, Thompson): 26.8 µg/kg 
Lab code Result (µg/kg) za-score 
1 83.8 -1.43
4 91 -1.16
9 124 0.07
10 124.03 0.07
11 132.1 0.38
12 247.5 4.68
14 96 -0.97
15 94 -1.05
16 112 -0.37
17 112 -0.37
18 217.2 3.55
19 87 -1.31
20 93 -1.08
21 120.5 -0.06
22 205 3.10
23 99.9 -0.83
25 190 2.54
27 119.5 -0.09
28 159.4 1.40
30 121.9 0.00
32 200 2.91
33 115 -0.26
35 126 0.15
36 109 -0.49
37 119.5 -0.09
Annex 10 continued  Results for the analysis of dapson 
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Figure a: Graphical representation of the reported results. The X ± 2σp lines are calculated according to equation 
I in §4.2.4. 
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Figure b: Graphical representation of za-scores. 
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Annex 11 Results for the analysis of sulfadimidine 
Sulfadimidine 
Assigned value: 90.1 µg/kg 
Uncertainty of assigned value: 3.25 µg/kg 
Target standard deviation (Horwitz, Thompson): 19.8 µg/kg 
Lab code Result (µg/kg) za-score 
1 86 -0.21
4 85.8 -0.22
5 77 -0.66
6 33 -2.88
9 88 -0.10
10 93.5 0.17
11 74.2 -0.80
12 82.4 -0.39
14 99 0.45
15 94 0.20
16 81 -0.46
17 64.3 -1.30
18 67.6 -1.13
19 112 1.11
20 125 1.76
21 72.1 -0.91
22 124 1.71
23 125 1.76
25 91.5 0.07
27 83.3 -0.34
28 91.5 0.07
30 110.7 1.04
32 91 0.05
33 75 -0.76
35 91 0.05
36 94 0.20
37 124.5 1.74
 
Annex 11 continued Results for the analysis of sulfadimidine 
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Figure a: Graphical representation of the reported results. The X ± 2σp lines are calculated according to equation 
I in §4.2.4. 
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Figure b: Graphical representation of za-scores. 
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Annex 12 Results for the analysis of sulfachloropyridazine 
Sulfachloropyridazine 
Assigned value: 64.3 µg/kg 
Uncertainty of assigned value: 3.49 µg/kg 
Target standard deviation (Horwitz, Thompson): 14.1 µg/kg 
Lab code Result (µg/kg) zai-score 
1 73 0.62
4 66.7 0.17
5 63 -0.09
6 18 -3.08
10 73.1 0.62
12 63.3 -0.07
15 69 0.33
16 49 -1.02
17 36.5 -1.85
18 34.7 -1.97
20 83 1.32
21 51.7 -0.84
22 89 1.75
23 74.4 0.71
25 61.1 -0.21
27 82.8 1.31
35 57 -0.49
36 68 0.26
 
Annex 12 continued Results for the analysis of sulfachloropyridazine 
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Figure a: Graphical representation of the reported result. The X ± 2σp lines are calculated according to equation 
III in §4.2.4. 
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Figure b: Graphical representation of zai-scores.  
X 
 X + 2σp 
 X - 2σp 
 RIKILT Report 2010.010 62 
Annex 13 Results for the analysis of dapson 
Dapson 
Assigned value: 3.35 µg/kg 
Uncertainty of assigned value: 0.29 µg/kg 
Target standard deviation (Horwitz, Thompson): 0.74 µg/kg 
Lab code Result (µg/kg) z'ai-score 
4 1.42 -2.12
10 3.25 -0.11
12 4.1 0.95
16 1.62 -1.90
21 3.6 0.32
22 3.7 0.44
27 4.25 1.14
28 3.7 0.44
30 4.8 1.83
33 2 -1.48
35 3.0 -0.38
36 2 -1.48
37 4.3 1.20
 
Annex 13 continued  Results for the analysis of dapson 
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Figure a: Graphical representation of the reported results. The X ± 2σp lines are calculated according to equation 
IV in §4.2.4. 
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Figure b: Graphical representation of z'ai-scores.  
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